Skip to main content

Table 1 Health resource utilisation considered in derivation of cost of HCV Health-states

From: Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study

Input Mild Mod Comp. Cirrhosis Decomp. Cirrhosis HCC Transplant Year 1 Transplant > Year 1 SVR Source
OPD bundlea Institution costs
 FBC          
 Renal profile          
 Liver profile          
 Coagulation screen          
 AFP          
 HCV Viral load          
 Liver US          
 Staff Costs          HSE salary scale 2010
Liver Biopsy HSE DRG 2011
OGDb HSE DRG 2011
Hepatology Medical review Micro-costing
Hepatology Nursing review Micro-costing
Inpatient Admission HSE DRG 2011
Sorafenib Micro-costingd
TACEc Institution cost
Oncology/ Palliative OPD HSE DRG 2011
Dermatology OPD HSE DRG 2011
Hepatology Dayward review HSE DRG 2011
Pre-transplant workup Micro-costing
3 months Prophylaxis Micro-costingd
Immunosuppression Micro-costingd
Diuretic/Beta-blocker Micro-costingd
  1. Mod moderate, Comp. cirrhosis Compensated cirrhosis, Decomp. Cirrhosis decompensated cirrhosis, HCC hepatocellular carcinoma, Transplant Year 1 First 12 months of liver transplantation, Transplantation > Year 1 Transplantation After First 12 months, SVR Sustained Viral Response, HSE Health Service Executive, DRG Diagnostic Related Group, PCRS Patient Care Reimbursement Service, OPD outpatient, aBundle: FBC Full Blood Count, Renal Profile Urea, Creatinine, Sodium, Potassium, Bicarbonate; Liver Profile Albumin, Alanine amino transaminase, Aspartate amino transaminase, Gamma glutamyl transferase, Bilirubin, Lactate Dehydrogenase; Coagulation Screen Prothrombin Time, Activated partial thromboplastin time, International Normalised Ratio, AFP Alpha fetoprotein, bOGD Oesophago-gastro-duodenoscopy, cTACE Transarterial chemoembolisation, dUnit cost of drug sourced from the Primary Care Reimbursement System